Until studies several connected barriers to reversible organ preservation. Its science program covers delivery of cryoprotectants through organ vasculature, molecular design and screening, controlled cooling, and even rewarming.
The company also assays organ health after rewarming, connecting engineering work to the condition of preserved tissue. Its published progress concerns research and preclinical model organs, so clinical effectiveness remains to be established.
Until is developing an organ cryopreservation platform for the transplantation system. The near-term goal is to preserve donated organs longer, while its broader research examines the principles of reversible biological preservation.
Its September 2025 Series A announcement reported $58 million in new financing and more than $100 million raised overall. The company described molecular agents, perfusion protocols, hardware, and preclinical organ work as parts of its development program.
Until researches reversible cryopreservation systems for donor organs. Its approach spans perfusion, cryoprotectant molecules, cooling, rewarming, and tests that assess organ health after preservation.
The company develops molecular agents, surgical and perfusion protocols, and cooling and rewarming hardware together. Its September 2025 update described work progressing from neural tissue slices to preclinical model organs.
